Boston Scientific (NYSE:BSX) sees a price target increase from Citigroup despite a recent share price decline.
The company reports a 7% drop in net income but exceeds revenue forecasts with a 19% surge, driven by cardiovascular product sales.
Boston Scientific’s adjusted EPS of $0.63 beats projections, underscoring effective core operation management.
Boston Scientific (NYSE:BSX) is a leading medical device company known for its innovative products in the cardiovascular, endoscopy, and urology fields. The company competes with other major players like Medtronic and Abbott Laboratories. On October 24, 2024, Citigroup maintained its “Buy” rating for BSX, reflecting confidence in the company’s future prospects. At that time, the stock was priced at $87.45.
Citigroup’s decision to raise the price target for Boston Scientific from $92 to $98 indicates optimism about the company’s potential growth. This comes despite the recent decline in BSX’s share price following its third-quarter financial results. The stock experienced a decrease of 0.64%, or $0.56, on the day of the announcement, fluctuating between $83.27 and $87.58.
Boston Scientific’s third-quarter results revealed a 7% year-over-year drop in net income to $469 million, missing the $543 million consensus estimate. The GAAP earnings per share (EPS) was $0.32, below the expected range of $0.36 to $0.38. However, the adjusted EPS of $0.63 exceeded projections, showcasing the company’s ability to manage its core operations effectively.
Despite the profit shortfall, Boston Scientific’s revenue surged 19% to $4.21 billion, surpassing forecasts. This growth was largely driven by a 25% increase in sales of its cardiovascular products, which reached $2.73 billion. The strong performance in this segment highlights the company’s competitive edge in the medical device industry.
Boston Scientific’s market capitalization is approximately $128.78 billion, with a trading volume of 18.02 million shares. Over the past year, the stock has reached a high of $88.79 and a low of $49.15. The company’s mixed update on its full-year forecast suggests a cautious yet optimistic outlook for the future.
